Navigation Links
New Report Analyzes Key Controversies in Multiple Sclerosis Treatment

SCOTTSDALE, Ariz., Nov. 14 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for MS therapies.

In this report, entitled "MedPredict Thought Leader Insight & Analysis: Multiple Sclerosis," physician experts discuss the key controversies emerging from ECTRIMS (European Committee for Treatment and Research in MS) 2007, including:

-- Early aggressive therapy vs. more conservative approaches.

-- The negative results from REGARD, and implications for the powering of

MS trials. The report offers predictions on results expected in the


-- The potential for pulmonary delivery of interferon and Copaxone.

-- The numerous orally available drugs in development for MS. The report

reviews the benefits and drawbacks of fingolimod, other S1Ps,

short-acting VLA4, teriflunomide, laquinimod, fampridine, fumarates and

other oral options, and predicts where they will fall on the

safety/efficacy spectrum.

-- The status and potential of a number of vaccine approaches.

-- Intriguing neuroprotection / neuroregeneration strategies, including

LINGO, anti-myelin-associated-glycoprotein MAb and remyelination MAb.

Drugs/Mechanisms mentioned in this report include: S1P agonists (fingolimod; Novartis, S1P1; Roche/Actelion, Sphingomab; Lpath, S1P1 modulators; Epix / Amgen), inhibitors of DNA synthesis/repair (teriflunomide; Sanofi-Aventis, cladribine; Ivax/Serono), potassium channel blockers (fampridine; Acorda, BNC-245; Bionomics), interferons (Avonex; Biogen, Rebif; Ares-Serono, Betaseron; Bayer-Schering and Biferonex; Biopartners Holdings), VLA4 inhibitors (Tysabri; Biogen/Elan, firategrast; GlaxoSmithKline, CDP-323; UCB/Biogen; ATL1102 (Antisense Therapeutics), B-cell inhibitors (rituximab; Biogen/Genentech/Roche, ocrelizumab; Genentech/Roche, CamPath/alemtuzumab; Genzyme / Bayer-Schering, ofatumumab; Genmab/GSK, GA-101; Glycart / Roche), Anti-CD-25 (daclizumab; PDL/Biogen/Roche), other autoimmune suppressants (laquinimod; Teva), myelin basic proteins (Copaxone; Teva, PI-2301 (Peptimmune), MBP8298; BioMS, BHT-3009; Bayhill, Tovaxin; Opexa, NeuroVax; Orchestra, VG-1000/RTL-1000; Artielle), fumartes (BG-12; Biogen), hormonal therapy (estriol; Pipex, testosterone; UCLA), anti-myelin-associated-glycoprotein MAb (GSK), Neurodex (dextromethorphan + quinidine; Avanir), Remyelination MAb (Acorda / Mayo).

About MedPredict

MedPredict ( maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

SOURCE MedPredict Market Research
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
(Date:10/11/2017)... ... 2017 , ... Disappearing forests and increased emissions are the main causes of ... year. Especially those living in larger cities are affected by air pollution related diseases. ... most pollution-affected countries globally - decided to take action. , “I knew I had ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
(Date:10/9/2017)... ... 2017 , ... The award-winning American Farmer television series will feature 3 Bar ... Tuesdays at 8:30aET on RFD-TV. , With global population estimates nearing ten billion ... continue to feed a growing nation. At the same time, many of our valuable ...
Breaking Biology Technology:
(Date:8/15/2017)... , Aug. 15 2017   ivWatch LLC , a medical ... (IV) therapy, today announced receipt of its ISO 13485 Certification, the ... the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the early detection ... "This is an important ...
(Date:6/14/2017)... , June 15, 2017  IBM (NYSE: IBM ) ... international tech event dedicated to developing collaboration between startups and ... on June 15-17. During the event, nine startups will showcase ... value in various industries. France ... the international market, with a 30 percent increase in the ...
(Date:5/6/2017)... , May 5, 2017 ... just announced a new breakthrough in biometric authentication ... exploits quantum mechanical properties to perform biometric authentication. These ... smart semiconductor material created by Ram Group and ... finance, entertainment, transportation, supply chains and security. Ram ...
Breaking Biology News(10 mins):